Jubilant Therapeutics
Biotechnology, 1430 Us Hwy 206 Ste 110, Bedminster, New Jersey, 07921, United States, 11-50 Employees
Who is JUBILANT THERAPEUTICS
Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoi...
Read More
-
Headquarters: 1430 Us Hwy 206 Ste 110, Bedminster, New Jersey, 07921, United States
-
Date Founded: 2019
-
Employees: 11-50
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from JUBILANT THERAPEUTICS
Jubilant Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Jubilant Therapeutics
Answer: Jubilant Therapeutics's headquarters are located at 1430 Us Hwy 206 Ste 110, Bedminster, New Jersey, 07921, United States
Answer: Jubilant Therapeutics's official website is https://jubilanttx.com
Answer: Jubilant Therapeutics's revenue is $1 Million to $5 Million
Answer: Jubilant Therapeutics's SIC: 2834
Answer: Jubilant Therapeutics's NAICS: 325412
Answer: Jubilant Therapeutics has 11-50 employees
Answer: Jubilant Therapeutics is in Biotechnology
Answer: Jubilant Therapeutics contact info: Phone number: Website: https://jubilanttx.com
Answer: Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases. The company’s leadership and scientific team are science-driven executives with global pharma background and experience in advancing innovative drug candidates into the clinic. Jubilant Therapeutics is headquartered in the U.S. with independent board and management, guided by globally renowned KOLs and SAB. Key Therapeutic Areas • Oncology • Auto-immune Disorders Portfolio • Novel PAD4 inhibitors targeting auto-immune disorders • Dual LSD1/HDAC6 inhibitors targeting cancer • Novel small molecule PD-L1 inhibitors • Novel brain penetrating PRMT5 inhibitors targeting cancer
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month